Patents by Inventor Gregory Tawa

Gregory Tawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230301984
    Abstract: Method embodiments are disclosed for treating retinal degeneration in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of compound, and/or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, or tautomer thereof, selected from 3-(dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride or a compound having a structure according to a formula selected from Formula I, II, or III, as described herein. In some non-limiting examples, the subject has retinitis pigmentosa, LCA, Stargardt’s macular dystrophy, cone-rod dystrophy, choroideremia or age-related macular degeneration.
    Type: Application
    Filed: July 1, 2021
    Publication date: September 28, 2023
    Applicant: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Anand Swaroop, Yu Holly Chen, Manju Swaroop, Wei Zheng, Gregory Tawa, Anupam Mondal, Samantha Papal, Wenwei Huang, Zhiji Luo
  • Patent number: 11654147
    Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: May 23, 2023
    Assignees: The Brigham and Women's Hospital, Inc., The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
  • Publication number: 20230000869
    Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).
    Type: Application
    Filed: June 7, 2021
    Publication date: January 5, 2023
    Inventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
  • Patent number: 11026947
    Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: June 8, 2021
    Assignees: The Brigham and Women's Hospital, Inc., The United States of America, as Represented by the Secretary, Dept, of Health and Human Services
    Inventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
  • Publication number: 20200179389
    Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).
    Type: Application
    Filed: April 26, 2018
    Publication date: June 11, 2020
    Inventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
  • Publication number: 20070065898
    Abstract: This invention provides a fluorescence polarization assay useful in the detection and evaluation of caspases inhibitors. This invention also provides novel fluorescent probes used in the fluorescence polarization assay, and methods for making the fluorescent probes, which have the Formula I: wherein the constituent variables are as defined herein.
    Type: Application
    Filed: September 21, 2006
    Publication date: March 22, 2007
    Applicant: Wyeth
    Inventors: Paul Dollings, Gregory Tawa, Ann Aulabaugh